Advertisement

Phytothérapie

, Volume 11, Issue 5, pp 272–283 | Cite as

Interactions pharmacocinétiques entre préparations à base de plantes et médicaments : une revue des absences d’interactions démontrées cliniquement

  • F. PetitetEmail author
Article de synthèse Pharmacognosie
  • 301 Downloads

Résumé

Le devenir du médicament dans l’organisme est sous l’influence de phénomènes physicochimiques de réactions enzymatiques ou d’intervention de protéines de transport. Le médicament est absorbé, distribué, métabolisé puis éliminé par l’organisme. Une préparation à base de plantes prise concomitamment au médicament peut agir sur l’un de ces mécanismes cinétiques et provoquer une interaction plante-médicament. L’interaction peut alors se traduire par un sous-dosage ou surdosage du médicament et l’apparition de conséquences cliniques, perte de l’effet thérapeutique ou apparition d’effets secondaires. Des études cliniques réalisées souvent chez le volontaire sain démontrent alors la réalité clinique de ces interactions. Nous nous sommes intéressés, dans cette revue, aux données négatives obtenues lors de ces études cliniques. Certaines associations entre préparations à base de plantes et médicaments n’ont, en effet, pas permis de mettre en évidence d’interactions pharmacocinétiques cliniquement décelables. Ces résultats « négatifs » sont tout aussi importants dans la pratique clinique puisqu’ils démontrent l’absence d’interaction dans la population étudiée.

Mots clés

Interactions plante-médicament Pharmacocinétique ADME Études cliniques 

Herbdrug pharmacokinetic interactions: a review of the absence of interactions with clinical incidence

Abstract

After administered, the drug behavior is submitted to physico-chemical phenomena, enzymatic reactions, or transport via transporter proteins. The drug compound is absorbed, distributed, metabolized, and eliminated. A natural ingredient, taken concomitantly with the drug, may induce a herbdrug pharmacokinetic interaction. As a consequence, the drug may be underdosed or overdosed and clinical incidence such as lack of efficacy or adverse events could be seen. Clinical studies performed on healthy volunteers have demonstrated the clinical relevance of these herb-drug pharmacokinetic interactions. In this review, we focused on reported negative pharmacokinetic herb-drug interaction results obtained clinically. Indeed, several herb and drug associations have been evaluated and no herb-drug interaction with clinical incidence were noticed. These “negative” results are of importance in clinical practice as they demonstrate the absence of interactions risk at least in the studied populations.

Keywords

Herb-drug interactions Pharmacokinetics ADME Clinical studies 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Bell EC, Ravis WR, Chan HM, Lin YJ (2007) Lack of pharmacokinetic interaction between St. John’s wort and prednisone. Ann Pharmacother 41: 1819–1824CrossRefGoogle Scholar
  2. 2.
    Bell EC, Ravis WR, Llyod KB, Stokes TJ (2007) Effect of St John’s wort supplementation on ibuprofen pharmacokinetics. Ann Pharmacother 41: 229–234PubMedCrossRefGoogle Scholar
  3. 3.
    Boasser JB, Odle BL (2012) Probable etoposide interaction with Echinacea. J Diet (Suppl 9): 90–95Google Scholar
  4. 4.
    Burstein AH, Horton RL, Dunn T, et al. (2000) Lack of effect of St John’s wort on carbamazepine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 68: 605–612PubMedCrossRefGoogle Scholar
  5. 5.
    Chow HH, Hakim IA, Vining DR, et al. (2006) Effects of repeated green tea catechin administration on human cytochrome P450 activity. Cancer Epidemiol Biomarkers Prev 15: 2473–2476PubMedCrossRefGoogle Scholar
  6. 6.
    Dasgupta A (2008) Herbal supplements and therapeutic drug monitoring: focus on digoxin immunoassays and interactions with St John’s wort. Ther Dru Monit 30: 212–217CrossRefGoogle Scholar
  7. 7.
    DiCenzo R, Shelton M, Jordan K, et al. (2003) Coadministration of milk thistle and indinavir in healthy subects. Pharmacotherapy 23: 866–870PubMedCrossRefGoogle Scholar
  8. 8.
    Donovan JL, DeVane CL, Chavin KD, et al. (2003) Siberian ginseng (Eleutherococcus senticosus) effects on CYP2D6 and CYP3A4 activity in normal volunteers. Drug Metab Dispo 31: 519–522CrossRefGoogle Scholar
  9. 9.
    Donovan JL, Chavin KD, DeVane CL, et al. (2004) Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. Drug Metab Dispo 32: 906–908CrossRefGoogle Scholar
  10. 10.
    Donovan JL, DeVane CL, Chavin KD, et al. (2004) Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metab Dispo 32: 1333–1336CrossRefGoogle Scholar
  11. 11.
    Fan L, Zhou G, Guo D, et al. (2011) The pregnan X receptor agonist St John’s wort has no effects on the pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet 50: 605–611PubMedCrossRefGoogle Scholar
  12. 12.
    Fasinu PS, Bouic PJ, Rosenkranz B (2012) An overview of the evidence and mechanism of herb-drug interactions. Frontiers Pharmacol 3: 1–19Google Scholar
  13. 13.
    Fuhr U, Beckmann-Knopp S, Jetter A, et al. (2007) The effect of silymarin on oral nifedipine pharmacokinetics. Planta Med 73: 1429–1435PubMedCrossRefGoogle Scholar
  14. 14.
    Gallicano K, Foster B, Choudhri S (2003) Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers. Br J Clin Pharmacol 55: 199–202PubMedCrossRefGoogle Scholar
  15. 15.
    Gorski JC, Huang SM, Pinto A, et al. (2004) The effect of Echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther 75: 89–100PubMedCrossRefGoogle Scholar
  16. 16.
    Greenblatt DJ, von Moltke LL, Luo Y, et al. (2006) Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. J Clin Pharmacol 46: 214–221PubMedCrossRefGoogle Scholar
  17. 17.
    Gurley BJ, Gardner SF, Hubbard MA, et al. (2002) Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 72: 276–287PubMedCrossRefGoogle Scholar
  18. 18.
    Gurley BJ, Gardner SF, Hubbard MA, et al. (2004) In vivo assessement of botanical supplementation on human cytochrome P450 phenotypes: citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 776: 428–440CrossRefGoogle Scholar
  19. 19.
    Gurley BJ, Gardner SF, Hubbard MA, et al. (2005) Clinical assessement of effects of botanical supplementation on cytochrome P450 phenotypes in the ederly: St John’s wort, garlic oil, Panax ginseng and ginkgo biloba. Drugs Aging 22: 525–529PubMedCrossRefGoogle Scholar
  20. 20.
    Gurley BJ, Gardner SF, Hubbard MA, et al. (2005) In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 77: 415–426PubMedCrossRefGoogle Scholar
  21. 21.
    Gurley B, Hubbard MA, Williams DK, et al. (2006) Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J Clin Pharmacol 46: 201–213PubMedCrossRefGoogle Scholar
  22. 22.
    Gurley BJ, Barone GW, Williams DK, et al. (2006) Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos 34: 69–74PubMedCrossRefGoogle Scholar
  23. 23.
    Gurley BJ, Swain A, Barone GW, et al. (2007) Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispo 35: 240–245CrossRefGoogle Scholar
  24. 24.
    Gurley BJ, Swain A, Williams DK, et al. (2008) Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St John’s wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol Nutr Food Res 52: 772–779PubMedCrossRefGoogle Scholar
  25. 25.
    Gurley BJ (2012) Pharmacokinetic herb-drug interactions (part 1): origins, mechanisms, and the impact of botanical dietary supplements. Planta Med 78: 1478–1489PubMedCrossRefGoogle Scholar
  26. 26.
    Gurley BJ, Fifer EK, Gardner Z (2012) Pharmacokinetic herb-drug interactions (part 2): drug interactions involving popular botanical dietary supplements and their clinical relevance. Planta Med 78: 1490–1514PubMedCrossRefGoogle Scholar
  27. 27.
    Hermann R, von Richter O (2012) Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions. Planta Med 78: 1458–1477PubMedCrossRefGoogle Scholar
  28. 28.
    Jiang X, Blair EY, McLachan AJ (2006) Investigation of herbal medicines on warfarin response in healthy subjects: a population pharmacokineticpharmacodynamic modeling approach. J Clin Pharmacol 46: 1370–1378PubMedCrossRefGoogle Scholar
  29. 29.
    Jiang X, Williams KM, Liauw WS, et al. (2005) Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 59: 425–432PubMedCrossRefGoogle Scholar
  30. 30.
    Jiang X, Williams KM, Liauw WS, et al. (2004) Effect of St John’s wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 57: 592–599PubMedCrossRefGoogle Scholar
  31. 31.
    Kim BH, Kim KP, Lim KS, et al. (2010) Influence of Ginkgo biloba extract on the pharmacodynamics effects and pharmacokinetic properties of ticlopidine: an open-label, randomized, two period, two treatment, two-sequence, single dose crossover study in healthy Korean male volunteers. Clin Ther 32: 380–390PubMedCrossRefGoogle Scholar
  32. 32.
    Lei HP, Wang G, Wang LS, et al. (2009) Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers. Ann Pharmacother 43: 726–731PubMedCrossRefGoogle Scholar
  33. 33.
    Malati CY, Robertson SM, Hunt JD, et al. (2012) Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants. J Clin Pharmacol 52: 932–939PubMedCrossRefGoogle Scholar
  34. 34.
    Markowitz JS, Donovan JL, DeVane L, et al. (2003) Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. J Clin Psychopharmacol 23: 576–581PubMedCrossRefGoogle Scholar
  35. 35.
    Markowitz JS, Donovan JL, DeVane L, et al. (2003) Multiple-dose of saw palmetto (Serenoa repens) did not alter cytochrome P-450 2D6 and 3A4 activity in normal volunteers. Clin Pharmacol Ther 74: 536–542PubMedCrossRefGoogle Scholar
  36. 36.
    Markowitz JS, DeVane L, Chavin KD, et al. (2003) Effect of garlic (Allium sativum L.) supplementation on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Clin Pharmacol Ther 74: 170–177PubMedCrossRefGoogle Scholar
  37. 37.
    Mateo-Carrasco H, Galvez-Contreras MC, Fernandez-Gines FD, Nguyen TV (2012) Elevated liver enzymes resulting from an interaction between raltegravir and Panax ginseng: a case report and brief review. Drug Metab Drug Interact 27: 171–175CrossRefGoogle Scholar
  38. 38.
    Mauro VF, Mauro LS, Kleshinski JF, et al. (2003) Impact of Ginkgo biloba on the pharmacokinetics of digoxin. Am J Ther 10: 247–251PubMedCrossRefGoogle Scholar
  39. 39.
    Mills E, Wilson K, Clarke M, et al. (2005) Milk thistle and indinavir: a randomized controlled pharmacokinetics study and metaanalysis. Eur J Clin Pharmacol 61: 1–7PubMedCrossRefGoogle Scholar
  40. 40.
    Mohutsky MA, Anderson GD, Miller JW, Elmer GW (2006) Ginkgo biloba: evaluation of CYP2C9 drug interactions in vitro and in vivo. Am J Ther 13: 24–31PubMedCrossRefGoogle Scholar
  41. 41.
    Molto J, Valle M, Miranda C, et al. (2011) Herb-drug interaction between Echinacea purpurea and darunavir-ritonavir in HIV-infected patients. Antimicrob Agents Chemother 55: 326–330PubMedCrossRefGoogle Scholar
  42. 42.
    Morimoto T, Kotegawa T, Tsutsumi K, et al. (2004) Effect of St John’s wort on the pharmacokinetics of theophylline in healthy volunteers. J Clin Pharmacol 44: 95–101PubMedCrossRefGoogle Scholar
  43. 43.
    Nieminen TH, Hagelberg NM, Saari TI, et al. (2010) St John’s wort greatly reduces the concentrations of oral oxycodone. Eur J Pain 14: 854–859PubMedCrossRefGoogle Scholar
  44. 44.
    Petitet F (2012) Interactions pharmacocinétiques entre préparations à base de plantes et médicament: une revue de l’importance clinique. Phytothérapie 10: 170–182CrossRefGoogle Scholar
  45. 45.
    Piscitelli SC, Formentini E, Burstein AH, et al. (2002) Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy 22: 551–556PubMedCrossRefGoogle Scholar
  46. 46.
    Posadzki P, Watson L, Ernst E (2012) Herb-drug interactions: an overview of systematic reviews. Br J Clin Pharmacol (sous presse)Google Scholar
  47. 47.
    Rao BN, Srinivas M, Kumar YS, Rao YM (2007) Effect of silymarin on the oral bioavailability of ranitidine in healthy human volunteers. Drug Metabol Drug Interact 22: 175–185PubMedCrossRefGoogle Scholar
  48. 48.
    Rivera CA, Ferro CL, Bursua AJ, Gerber BS (2012) Probable interaction between Lycium barbarum (Goji) and warfarin. Pharmacotherapy (sous presse)Google Scholar
  49. 49.
    Robertson SM, Davey RT, Voell J, et al. (2008) Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects. Curr Med Res Opin 24: 591–599PubMedCrossRefGoogle Scholar
  50. 50.
    Roby CA, Dryer DA, Burstein AH (2001) St John’s wort: effect on CYP2D6 activity using dextromethorphan-dextrorphan ratios. J Clin Psychopharmacol 21: 530–532PubMedCrossRefGoogle Scholar
  51. 51.
    Salman SA, Amrah S, Wahab MS, et al. (2010) Modification of propranolol’s bioavailability by Eurycoma longifolia water-based extract. J Clin Pharm Ther 35: 691–696PubMedCrossRefGoogle Scholar
  52. 52.
    Sandhu RS, Prescilla RP, Simonelli TM, Edwards DJ (2003) Influence of goldenseal root on the pharmacokinetics of indinavir. J Clin Pharmacol 43: 1283–1288PubMedCrossRefGoogle Scholar
  53. 53.
    Sugimoto K, Ohmori M, Tsuruoka S, et al. (2001) Different effects of St John’s wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 70: 518–524PubMedCrossRefGoogle Scholar
  54. 54.
    Tankanow R, Tamer HR, Streetman DS, et al. (2003) Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha). J Clin Pharmacol 43: 637–642PubMedGoogle Scholar
  55. 55.
    Uchida S, Yamada H, Li XD, et al. (2006) Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J Clin Pharmacol 46: 1290–1298PubMedCrossRefGoogle Scholar
  56. 56.
    Wang Z, Gorski JC, Hamman MA, et al. (2001) The effect of St John’s wort (hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 70: 317–326PubMedGoogle Scholar
  57. 57.
    Wienkers LC, Health TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nature Rev Drug Discov 4: 825–833CrossRefGoogle Scholar
  58. 58.
    Yoshioka M, Ohnishi N, Koishi T, et al. (2004) Studies on interactions between functional foods or dietary supplements and medecines. IV. Effects of Ginkgo biloba leaf extract on the pharmacokinetics and pharmacodynamics of nifedipine in healthy volunteers. Biol Pharm Bull 27: 2006–2009PubMedCrossRefGoogle Scholar
  59. 59.
    Zadoyan G, Rokitta D, Klement S, et al. (2012) Effect of Ginkgo biloba special extract EGb 761 on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers. Eur J Clin Pharmacol 68: 553–560PubMedCrossRefGoogle Scholar
  60. 60.
    Zuo XC, Zhang BK, Jia SJ, et al. (2010) Effects of Ginkgo biloba extracts on diazepam metabolism: a pharmacokinetic study in healthy chinese male subjects. Eur J Clin Pharmacol 66: 503–509PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag France 2013

Authors and Affiliations

  1. 1.HerbéoBordeauxFrance

Personalised recommendations